Fusion Antibodies, a trusted CRO, delivers quick and reliable results of Antibody sequencing with unprecedented professionalism. In addition to our services, we offer tailor-made options that meet your specific research and derivative requirements. Our unmatched strength and expansive knowledge base in this highly skilled area of research helps accelerate your discovery and validation process. Our pioneering services have garnered us the position of a recognized leader in Monoclonal Antibody Sequencing. We provide for deriving a sequence from any anti-body producing cell line. From a select few revered names in the business of protein sequencing, we are one of the companies to have also sequenced dead hybridomal cells. For more than 8 years, we have delivered more than 500 antibody sequences for a variety of species including mouse, rat, bovine, human guinea pig, hamster, rabbits and human antibody secreting EBV cell lines. For any given kind of application, you can rest assured of our sequencing methodology for quality, consistency and accurate results.
In the field of molecular biological research, the use of sequencing is for determining the existence of antigen binding residues, and the nature of such antigen binding residues. These have become an important base in understanding and deploying research in biochemistry, molecular biology, and medicine. Monoclonal antibodies (mAb or moAb) are structurally identical monospecific. A specific type of B-lymphocytes produces these, which are all clones generated from a single parent cell. This method is deployed as it makes possible for synthesizing monoclonal anti-bodies, which specifically bind to a given substance €" almost any substance €" for detecting or purifying that substance. From the several methods, protein sequencing method like Edman degradation, MS, HPLC/MS, etc. are more commonly used for deriving results in sequencing. Antibody sequencing can be accomplished using several methods adopted worldwide, many of which are exorbitantly expensive. Alternatively, DNA sequencing is a relatively, cheaper technology for application in sequencing.
Monoclonal Antibodies are required in various academic, medical and commercial applications, especially clinical research. Several diagnostic tests used for determining small amounts of drugs, toxins or hormones, e.g. monoclonal anti-bodies are used in pregnancy test kits require the presence of anti-bodies. Another more known diagnostic, which uses monoclonal sequencing technology, is the diagnosis of AIDS by the ELISA test. Monoclonal sequenced anti-bodies is also extensively used in the radioimmunodetection and radioimmunotherapy of cancer amongst which, certain new methods can even target only the cell membranes of cancerous cells. In November 1997, the FDA approved Ritoxin, a new cancer drug based on this technology. The problem of organ rejection in patients, who have had organ transplants, has seen successful treatments developed using this technology called as OKT3, which is an anti-body to the T3 antigen produced by T cells of the human immune mechanism. A strain of single pathogen such as Neisseria gonorrhoeae have been successfully classified using this methodology. Quite a few traditionally considered "untreatable" viral diseases have found solutions developed using Monoclonal Sequencing of anti-bodies. At the pace at which current clinical research is leaping ahead, several research specialists hold the opinion that this process could be an important tool in the race to defeat HIV virus, and cure AIDS.
In the field of molecular biological research, the use of sequencing is for determining the existence of antigen binding residues, and the nature of such antigen binding residues. These have become an important base in understanding and deploying research in biochemistry, molecular biology, and medicine. Monoclonal antibodies (mAb or moAb) are structurally identical monospecific. A specific type of B-lymphocytes produces these, which are all clones generated from a single parent cell. This method is deployed as it makes possible for synthesizing monoclonal anti-bodies, which specifically bind to a given substance €" almost any substance €" for detecting or purifying that substance. From the several methods, protein sequencing method like Edman degradation, MS, HPLC/MS, etc. are more commonly used for deriving results in sequencing. Antibody sequencing can be accomplished using several methods adopted worldwide, many of which are exorbitantly expensive. Alternatively, DNA sequencing is a relatively, cheaper technology for application in sequencing.
Monoclonal Antibodies are required in various academic, medical and commercial applications, especially clinical research. Several diagnostic tests used for determining small amounts of drugs, toxins or hormones, e.g. monoclonal anti-bodies are used in pregnancy test kits require the presence of anti-bodies. Another more known diagnostic, which uses monoclonal sequencing technology, is the diagnosis of AIDS by the ELISA test. Monoclonal sequenced anti-bodies is also extensively used in the radioimmunodetection and radioimmunotherapy of cancer amongst which, certain new methods can even target only the cell membranes of cancerous cells. In November 1997, the FDA approved Ritoxin, a new cancer drug based on this technology. The problem of organ rejection in patients, who have had organ transplants, has seen successful treatments developed using this technology called as OKT3, which is an anti-body to the T3 antigen produced by T cells of the human immune mechanism. A strain of single pathogen such as Neisseria gonorrhoeae have been successfully classified using this methodology. Quite a few traditionally considered "untreatable" viral diseases have found solutions developed using Monoclonal Sequencing of anti-bodies. At the pace at which current clinical research is leaping ahead, several research specialists hold the opinion that this process could be an important tool in the race to defeat HIV virus, and cure AIDS.
SHARE
